Conference Proceedings

First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK plus ) NonSmall Cell Lung Cancer

A Shaw, T Bauer, T Takahashi, C Balk, Y Goto, A Polli, M Carpentieri, J Martini, B Solomon

JOURNAL OF THORACIC ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2018

DOI: 10.1016/j.jtho.2018.08.863

University of Melbourne Researchers

Citation metrics

4Web of Science
6Dimensions

Keywords

Tyrosine Kinase Inhibitor
Alk-Positive Nsclc
Lymphoma
2.1 Biological and Endogenous Factors
Rare Diseases
Respiratory System
Women'S Health
Lung
Oncology
Lorlatinib
Hematology
Science & Technology
3202 Clinical Sciences
32 Biomedical and Clinical Sciences
Lung Cancer
Cancer
3211 Oncology and Carcinogenesis
Lymphatic Research
Life Sciences & Biomedicine